Daniel Spratt, MD, outlines the limitations of PSA-, T stage-, and Gleason-based risk stratification and explains how AI-derived, continuous risk estimates could address them.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
Radiotracer choice, cyclotron versus generator supply chains, and shifting reimbursement policy all shape which patients can access PSMA PET, according to two physicians who built imaging capacity directly into their practices.
Molecular imaging has displaced conventional CT and bone scans as the first-line staging tool in prostate cancer, but a radiation oncologist and a urologist explain where conventional imaging still holds value.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Rahul Mehan, MD, explains when traditional resective procedures still make more sense than office-based options, shares his top advice for urologists early in adoption, and previews the minimally invasive technologies he's watching next.
Two years into offering drug-coated balloon dilation for BPH, Rahul Mehan, MD, compares his outcomes with the PINNACLE trial (NCT04131907), walks through sizing and patient selection, and details the recovery and safety counseling patients need before treatment.
Rahul Mehan, MD, explains why patients are pushing back on daily BPH medication, how prostate anatomy shapes the choice between mechanical, thermal, and drug-coated therapies, and what's fueling the shift to office-based care.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and pCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
Closing out the discussion, Aurelie Garant, MD, and Daniel Welchons, MD, distill who's an appropriate candidate for combined procedures, where the evidence still needs to grow, and the single change they want colleagues to make.
Head-to-head data and a first-of-its-kind combined procedure suggest urologists and radiation oncologists can address BPH and prostate cancer treatment in a single, coordinated session.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
Early neurophysiology and pressure-flow research directly underpin modern urodynamics, whereas Turner-Warwick's restorative philosophy, according to Sasha Vereecken, BScN, RN.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.
Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.
Men with bothersome BPH heading into prostate radiotherapy face a ticking clock. Aurelie Garant, MD, and Daniel Welchons, MD, compare minimally invasive options for getting patients optimized without delaying treatment.
Complex anatomy doesn't rule patients out of rectal spacing—it often makes them the best candidates. Two physicians discuss selection, collaboration, and where AI-guided workflows are headed.
Independent urology faces stagnant Medicare pay, rising costs, prior auth burden, and consolidation pressure, Celeste Kirschner, CAE, MHSA, says.
John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.
Rising patient interest in TRT, GLP-1s, and peptide stacking requires clinicians to anchor conversations in evidence tiers, use baseline DEXA scans to monitor body composition, and engage patient goals without endorsing unsupported claims.
The data are compelling, but only if patients reach a medical oncologist. Joshua J. Meeks, MD, PhD, tackles the unresolved questions in MIBC care and lays out the referral steps every community urologist can take today.
With the recent FDA approval of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) in MIBC, Joshua J. Meeks, MD, PhD, maps the treatment timeline patients should expect and the skin reactions that warrant an urgent referral.
For the first time in 25 years, a nonplatinum regimen beats cisplatin-based chemotherapy head-to-head. Joshua J. Meeks, MD, PhD, breaks down the KEYNOTE-B15/EV-304 data driving that shift.
A single FDA update just erased the platinum-eligibility line dividing patients with MIBC. Joshua J. Meeks, MD, PhD, explains what changed on July 10 and why a new subcutaneous option could ease access for rural patients
